We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Illumina (ILMN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ILMN and the rest of the Medical group's stocks.
Illumina is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ILMN is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ILMN's full-year earnings has moved 5.40% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ILMN has gained about 50.53% so far this year. Meanwhile, stocks in the Medical group have gained about 1.62% on average. This means that Illumina is outperforming the sector as a whole this year.
Looking more specifically, ILMN belongs to the Medical - Biomedical and Genetics industry, which includes 341 individual stocks and currently sits at #66 in the Zacks Industry Rank. Stocks in this group have lost about 15.57% so far this year, so ILMN is performing better this group in terms of year-to-date returns.
ILMN will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Illumina (ILMN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ILMN and the rest of the Medical group's stocks.
Illumina is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ILMN is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ILMN's full-year earnings has moved 5.40% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ILMN has gained about 50.53% so far this year. Meanwhile, stocks in the Medical group have gained about 1.62% on average. This means that Illumina is outperforming the sector as a whole this year.
Looking more specifically, ILMN belongs to the Medical - Biomedical and Genetics industry, which includes 341 individual stocks and currently sits at #66 in the Zacks Industry Rank. Stocks in this group have lost about 15.57% so far this year, so ILMN is performing better this group in terms of year-to-date returns.
ILMN will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.